KYMR
NASDAQKymera Therapeutics Inc.
Website
News25/Ratings12
News · 26 weeks1080%
2025-10-262026-04-19
Mix5890d
- SEC Filings27(47%)
- Insider18(31%)
- Other8(14%)
- Earnings3(5%)
- Analyst2(3%)
Latest news
25 items- PRKymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report first quarter 2026 financial results on April 30, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERSEC Form 4 filed by Goodman Noah4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Chadwick Jeremy G4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Booth Bruce4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- PRKymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaKT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track designation previously granted for KT-621 for moderate to severe AD WATERTOWN, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe eosinophi
- INSIDERSEC Form 4 filed by Goodman Noah4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- PRKymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development CandidateKT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR) today announced that Gilead Sciences, Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera, under their strategic collaboration agreement. As a result, Kymera will realize a $45 million milestone payment. Gilead will progress the program into IND-enabling studies to support an IND filing in 2027.
- INSIDERSEC Form 4 filed by Chadwick Jeremy G4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 4 filed by Ridloff Elena4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 8-K filed by Kymera Therapeutics Inc.8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERSEC Form 4 filed by Chadwick Jeremy G4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)